Key Takeaway: The article discusses a poster presentation by Cho E and colleagues at the Society for Neuroscience annual meeting in November 2023. The research focuses on the role of sigma-2 receptor modulators CT1812 and CT2168 in a mouse model of Alzheimer's disease. This study aims to provide insights into potential therapeutic strategies for Alzheimer's.
Price reaction · baseline $1 (2023-11-09 close) · hit pre-market · 1 other CGTX headline(s) in the window, move may be shared
day 0 close · peak
+6.5%
day 1
+3%
day 3
+5%
Market Sentiment Analysis
POSITIVE FACTORS
Presentation at a prestigious conference indicates recognition.
Research focuses on potential treatments for Alzheimer's disease.
Use of proteomic analysis suggests a thorough scientific approach.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+35%
120-day peak, hindsight
Typical move
8.3%
average across 6 past catalysts
Cash runway
~33 mo
Minimal dilution risk
Lead asset
Oxytocin
Phase 2 · Oxidative Stress
Full Press Release Details
Cho E, Caldwell J, Pandey K, et al. A proteomic analysis to elucidate the role of sigma-2 receptor modulators CT1812 and CT2168 in a mouse model of Alzheimer’s disease . Poster presented Nov 2023 at: Society for Neuroscience (SfN) annual meeting ; Washington DC.
Frequently Asked Questions
What was presented at the Society for Neuroscience meeting?
The poster presented a proteomic analysis of sigma-2 receptor modulators CT1812 and CT2168.
What is the focus of the research?
The research investigates the role of sigma-2 receptor modulators in a mouse model of Alzheimer's disease.
Who conducted the research on CT1812 and CT2168?
The research was conducted by Cho E, Caldwell J, Pandey K, and colleagues.